Purchase THJ-018

Discount program, second-order - 5%OFF, third-order - 7% OFF

With us securely! - re-shipment guarantees.

We always offer new legal products of impeccable quality.

Please make sure that the product is legal in your country and not under control before ordering.

We do not sell pharmaceutical products or controlled products.

Where to buy THJ-018 for sale

THJ-018 (SGT-17) is an indazole derivative of JWH-018; it is a synthetic cannabinoid drug sold online as a designer drug.

SGT-17 is a synthetic cannabinoid that is the indazole analog of JWH-018. It has been sold online as a designer drug with no reported recreational use.

THJ-018 (SGT-17, AM-2233) is a synthetic cannabinoid that acts as a potent agonist for the cannabinoid receptors CB1 and CB2.

THJ-018 (SGT-17) is a synthetic cannabinoid indazole analog of JWH-018 and has been sold online as a designer drug. It has been associated with cases of intoxication and fatalities, particularly in the United States, before being regulated.

THJ-018 (SGT-17) is a synthetic cannabinoid indazole analog of JWH-018 and has been sold online as a designer drug. Propylhexedrine exhibits stimulant activity in animals, but it lacks both the piperidine group and a carbonyl group found in methamphetamine.

THJ-018 is a synthetic cannabinoid indazole analog of JWH-018 and has been sold online as a designer drug. The drug has never been properly researched in humans. Still, it is believed to act as a potent agonist for the cannabinoid receptors, as a full agonist at CB1 receptors and as a partial agonist at CB2 receptors. It has a high affinity for these sites, with an affinity for the human CB1 receptor approximately equal to that of JWH-018.

THJ-018 is a synthetic cannabinoid sold online as a designer drug. It has never been properly researched in humans, but it is believed to act as a potent agonist at the cannabinoid receptors and as a full agonist at CB1.

THJ-018 is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It binds to CB1 and CB2 receptors with high affinity and acts as a full agonist but shows a higher affinity for CB1 receptors than JWH-018.

THJ-018 is a synthetic cannabinoid that acts as a potent agonist for the CB1 and CB2 receptors, with a similar affinity to the cannabis derivative JWH-018.

Cannabinoids are a class of diverse chemical compounds active in the brain and throughout the peripheral nervous system. The best-known cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis.

THJ-018 is a synthetic cannabinoid that was first reported in 2009.

THJ-018 is an indazole analog of JWH-018, invented by Alexandros Makriyannis at Northeastern University in 2009.

THJ-018 is a synthetic cannabinoid that binds to the CB1 receptor. Its chemical structure is similar to JWH-18 and AM-2201, which are illegal under the Controlled Substances Act. First detected in the Spring of 2013, THJ-018 has been involved in several documented intoxications, hospitalizations and deaths.

THJ-018 is a synthetic cannabinoid that resembles JWH-18, Pravadoline and Am-2201. It is often found in combination with other active ingredients.

THJ-018 is a synthetic cannabinoid that binds to CB1 cannabinoid receptors in the brain, which are responsible for pain perception, memory, coordination and time perception.

THJ-018, also known as APICA, is a synthetic cannabinoid drug chemically similar to JWH-18 and AM-2201. It is slightly less potent than JWH-18.

THJ-018 is a synthetic cannabinoid that is the indazole analog of JWH-018, a substance sold as a designer drug.

THJ-018 (SGT-17) is a synthetic cannabinoid indazole analog of JWH-018 and has been sold online as a designer drug. Commonly known as 4-methyl-naphthyl indazole, this compound was likely first synthesized by Pfizer in 2006.

THJ-018 is a synthetic cannabinoid that is the indazole analog of JWH-018.

THJ-018 is an analog of JWH-018, with a higher affinity for CB1 receptors and a lower affinity for CB2 receptors.